/,
Ko4i879
JAN 18 2005
Attachment 4
510(K) Summary of Safety and Effectiveness
This 510(K) Summary of Safety and Effectiveness for the Palomar StarLux™ Pulsed Light
System is submitted in accordance with the requirements of Safe Medical Device Act
(SMDA) of 1990 and follows the Office of Device Evaluation (ODE) guidance concerning
the organization and content of a 510(K) summary.
Applicant: Palomar Medical Technologies, Inc.
Address: 82 Cambridge St.
Burlington, MA 01803 .
781-993-2300
Contact Person: Marcy Moore
Telephone: 919-363-2432
Preparation Date: July 8, 2004
Device Trade Name: - Palomar Lux1064™ NdYAG Handpiece
Common Name: Lux1064™

Classification Name: Laser surgical instrument for use in General and
Plastic Surgery and in Dermatology
(see: 21 CFR 878-4810).

Product Code: GEX
Panel: 79

Legally-Marketed Predicate Device: StarLux™ Pulsed Light System (handpieces)

Lumenis Family of IPL & IPL/NdYAG, Candela
Gentle YAG, Laserscope LIRA

System Description: The Lux1064™ is a versatile, light-based medical
device consisting of a base unit and handpiece
attachments.

Intended Use of the Device: The Lux1064™ is a light-based medical device
designed for effective removal of unwanted hair,
permanent hair reduction, PFB, treatment of wrinkles,
and the treatment of vascular and pigmented lesions.

18

/ Ay
Koy 1¥ 74 f

Performance Data: The differences in the specifications of the
Lux1064™ and the predicate devices do not result
in different performance or raise new questions of
safety or efficacy.

Conclusion: Based on the foregoing, the Lux1064™ System is
substantially equivalent to the legally-marketed

‘ claimed predicate devices, i.e., the Lumenis
IPL/NdYAG, Candela Gentle YAG, and Laserscope
Lyra series.
19

oy
j DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
% &
“ae Food and Drug Administration
9200 Corporate Boulevard
JAN 13 7005 Rockville MD 20850
Palomar Medical Technologies, Inc.
c/o Ms. Marcy Moore
Manager of Clinical Studies
131 Kelekent Lane
Cary, North Carolina 27511
Re: K041879
Trade/Device Name: Palomar Lux1064™ Nd:YAG Handpiece
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and
plastic surgery and in dermatology :
Regulatory Class: II
Product Code: GEX
Dated: October 22, 2004
Received: October 25, 2004
Dear Ms. Moore:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class HI (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may’
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including. but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820): and if applicable. the electronic
product radiation control provisions (Sections 531-342 of the Act): 21 CFR 1000-1050.

Page 2 — Ms. Marcy Moore
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally .
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http://www. fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

eran C Pie V cot
£eCelia M. Witten, Ph.D., M.D.
; Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and Radiological Health
Enclosure

INDICATIONS FOR USE STATEMENT

$10(K) Number: K041879
Device Name: Palomar Lux1064™ Nd: YAG Handpiece
Indications for Use:

The Lux1064™ handpiece is indicated for:

« ©The removal of unwanted hair for skin types J-VI, and to effect
stable long-term permanent hair reduction.

« The treatment of benign pigmented lesions such as, but not
limited to, senile lentigines (age spots), solar lentigos (sun
spots), pigmented seborrheic keratoses, nevi, chloasma, caféau-lait macules, and plaques.

e Verrucae, skin tags, seborrheic keratosis,

« Tattoos (significant reduction in the intensity of black and/or
blue-black tattoos).

e The Luxi064™ js indicated for pigmented lesions to reduce
lesion size, for patients with lesions that would potentially
benefit from aggressive treatment, and for patients with lesions
that have not responded to other laser/light treatments.

¢ The treatment of vascular lesions such as but not limited to,
port wine stains, hemangiomas, telangiectasias, rosacea, Venus
lake, facial and leg veins.

¢ The Luxl064™ is also indicated for the reduction of red
pigmentation in hypertrophic and keloid scars where
vascularity is an integral part of the scar.

* Coagulation and hemostasis of soft tissue.

« Treatment of wrinkles.

e Pseudofolliculitis barbae (PFB)

Prescription use VO OR Over-the-Counter Use____
(per 21 CFR 801.109)

(Please do not write below this line - Continue on another page if needed)
Senne pemenmeneeeee eee
Concurrence of CDRH, Office of Device Evaluation (ODE)

Aa

(Division Sign-Off)

Division of General, Restorative,

and Neurological Devices

; GIST 9
510(k) Number “01/577

